Table 1.
Inhibitors that control metabolic signaling.
| Inhibitor | Chemical Structure | Mode of Regulation | Disease Types | References |
|---|---|---|---|---|
| Glycolysis inhibitors | ||||
| 2-DG |
|
Competitively inhibits the production of glucose-6-phosphate | Acute lung and kidney injury in mice; COVID-19 and herpes simplex virus infected patients |
91-93 |
| 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one |
|
Binds to PFKFB3 in a dose-dependent manner | Acute lung injury mice model | 88 |
| 4-Octyl itaconate |
|
Binds to Cys22 of GAPDH | Endotoxaemia mice model | 95 |
| Capsaicin |
|
Binds to Cys424 of PKM2 | Septic shock mice model; neuropathic pain and amyotrophic lateral sclerosis patients | 96 |
| iminostilbene or shikonin |
|
Binds to PKM2 in a dose-dependent manner | Myocardial ischemia-reperfusion injury and non-alcoholic fatty liver disease mice models | 97, 99 |
| TEPP-46 |
|
Promotes PKM2 tetramer formation | Encephalomyelitis and multiple sclerosis mice models | 20 |
| DASA-58 |
|
Promotes PKM2 tetramer formation | Hepatic fibrosis mice model | 18, 101 |
| D5 |
|
Promotes PKM2 tetramer formation | Ulcerative colitis mice model | 102 |
| NADPH oxidase inhibitors | ||||
| Apocynin |
|
Blocks p47phox membrane translocation | Corneal alkali burn mice model; sodium-induced declines in cutaneous microvascular function bronchial asthma patients |
104, 105, 148 |
| LDC7559 /NA-11 |
|
Binds to the AMP/ADP allosteric activation site | Neutrophil-induced bronchial epithelial damage mice model | 28 |
| GKT137831 (Setanaxib) |
|
Direct inhibitor of NOX1 and NOX4 | Type 2 diabetes and primary biliary cholangitis patients |
Clinical trial No. NCT02010242, NCT03226067 |
| ML090 |
|
NOX5 inhibitor | Stroke patients | 107 |
| ROS Scavenger | ||||
| MitoQ |
|
A mitochondria-targeted antioxidant | Tissue hypoxia induced by neurological deficits in mice; improve vascular function Parkinson's disease exercise-induced mitochondrial DNA damage in patients |
108-112 |
| Tiron (sodium 4,5-dihydroxybenzene-1,3-disulfonate) |
|
A mitochondria-targeted antioxidant | Airway remodeling and erectile dysfunction in mice | 113-115 |
| mito2HOBA (4-(4-aminomethyl)-3-hydroxyphenoxy)butyl)-triphenylphosphonium) |
|
A mitochondria-targeted isolevuglandins scavenger | N/A | 116 |
| nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) |
|
Activate enzymes control biosynthesis of NAD | Aged mice; and prediabetes patients | 117, 118 |
| Itaconate derivative | ||||
| 4-Octyl itaconate |
|
Protects against lethality and systemic inflammation induced by LPS | Septic shock mice model | 69 |
| cGAS inhibitors | ||||
| PF-06928215 |
|
Binds to the catalytic domain of cGAS | Aged mice and high fat diet-induced cardiac anomalies in mice | 81 |
| Compounds 18, S2, and S3 |
|
Binds to the catalytic domain of cGAS | N/A | 119 |
| RU.521 |
|
Binds to residues Arg364 and Tyr421 of cGAS | Subarachnoid hemorrhage-induced brain injury, cerebral venous sinus thrombosis, acute liver injury, rheumatoid arthritis, and postoperative cognitive dysfunction models in mice |
120 |
| G108 and G150 |
|
Binds to the active site of cGAS | N/A | 121 |
| Cu-32, Cu-76, and their analogs |
|
Binds to the dimer interface of human cGAS | N/A | 122 |
| hydroxychloroquine sulfate, chloroquine, and quinine |
|
Inhibits cGAS upon dsDNA stimulation of | Antineoplastic effects in mice; rheumatoid arthritis, systemic lupus rythematosus, and SARS-CoV-2 infection in patients | 123 |
| X6 |
|
Blocks interaction of cGAS to dsDNA | N/A | 124 |
| Suramin |
|
Inhibits the enzymatic activity of cGAS | Osteoarthritis, chikungunya virus infection, and diabetic nephropathy in mice | 127, 128, Clinical trial No. NCT04496596 |
| Aspirin |
|
Binds to residues Lys384, Lys394, or Lys414 of cGAS | Atherosclerotic cardiovascular disease, diabetes, and periodontitis in mice; patients with atherosclerotic cardiovascular disease | 129 |
| STING inhibitor | ||||
| Nitrofuran derivative C-170, C-171, C-176, C-178, and the indoles derivative H-151 |
|
Disrupt assembly of the multimeric STING complexes | N/A | 83, 131 |
| SP23 |
|
Blocks assembly of the multimeric STING complexes | Mice renal cell carcinoma model | 132 |
| Nitro-fatty acids (NO2-FAs) | Not disclosed | Binds to residues Cys88, Cys91, and His16 of STING | Mice myocardial fibrosis model | 133 |
| BPK-21 and BPK-25 |
|
Binds to residue Cys 91 of STING | N/A | 134 |
| Compound 18 |
|
Binds to residues Thr263 and Thr267 of STING | N/A | 135 |
| Astin C |
|
Binds to the cyclic dinucleotide sites of STING | Colitis and cardiac anomalies in mice | 82 |
| Compound 13 |
|
A pathway-specific antagonists of cyclic GMP-AMP synthase | N/A | 136 |
| AIM2 inhibitors | ||||
| CRID3 |
|
Inhibits formation of ASC complexes | Spinal cord injury in mice | 137 |
| Shikonin |
|
Dampens formation of ASC specks and directly inhibit caspase-1 enzymatic activity | Acute liver injury, ovarian cancer, skin diseases, wound healing, and lung cancer in mice | 138 |
| J114 |
|
Blocks interaction between AIM2 and ASC and inhibit ASC oligomerization | Mice keratitis model | 139 |
| Obovatol |
|
Inhibits formation of ASC pyroptosome | Mice Alzheimer's disease, colorectal cancer, bone disorders, and hepatocellular carcinoma models | 140 |
| mTOR inhibitor | ||||
| Rapamycin |
|
Inhibits PI3K-Akt signaling, AMPK and mTOR activity | Glaucoma, lung injury, and aging in mice; tuberous sclerosis complex-associated tumors in patients | 141, 149 |